Literature DB >> 3056898

Human recombinant insulin-like growth factor I. I. Development of a serum-free medium for clonal density assay of growth factors using BALB/c 3T3 mouse embryo fibroblasts.

T L Riss1, K P Karey, B D Burleigh, D Parker, D A Sirbasku.   

Abstract

A serum-free clonal density growth assay was developed for the quantification of the biological activity of human recombinant insulin-like growth factor I (IGF-I). The assay measures IGF-I stimulated growth of Balb/c 3T3 cells cultured over 4 d on poly-D-lysine-coated plastic surfaces in a serum-free medium formulation composed of a 1:1 (vol/vol) mixture of Ham's F12 and Dulbecco's modified Eagle's media, supplemented with 3.0 ng/ml bovine basic fibroblast growth factor (bFGF), 10 micrograms/ml human transferrin, 100 micrograms/ml ovalbumin, and 1.0 microM dexamethasone. Low-temperature trypsinization of serum-supplemented stock cultures combined with the use of poly-D-lysine-coated plates made it unnecessary to use serum or fibronectin to promote cell attachment and survival. Serum-free growth conditions were optimized with respect to the concentrations of the supplements. Addition of IGF-I resulted in 3.5-fold more cells than control cultures without IGF-I after 4 d. Deletion of BFGF resulted in no IGF-I stimulation of growth. The concentrations of various preparations of IGF-I required to achieve one-half maximal stimulation of cell number (ED50) ranged between 1.25 and 4.7 ng/ml. In parallel assays, IGF-I was 6.6 times more potent than human recombinant insulin-like growth factor II and 32 times more potent than insulin. When cells were seeded into medium containing IGF-I, transferrin, ovalbumin, and dexamethasone but no bFGF, growth was minimal. Dose-response addition of bFGF showed an ED50 of 0.9 ng/ml. The methods reported are useful to monitor the biological potency of recombinant and natural-source growth factors as well as providing a new means of studying the multiple growth factor requirements of Balb/c 3T3 cells in culture.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056898     DOI: 10.1007/bf02620811

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  41 in total

1.  Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulinlike growth factor I.

Authors:  D R Clemmons; R G Elgin; V K Han; S J Casella; A J D'Ercole; J J Van Wyk
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

2.  Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding.

Authors:  F J Ballard; G L Francis; M Ross; C J Bagley; B May; J C Wallace
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

3.  An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.

Authors:  R G Elgin; W H Busby; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  The complete amino acid sequence of human brain-derived acidic fibroblast growth factor.

Authors:  G Gimenez-Gallego; G Conn; V B Hatcher; K A Thomas
Journal:  Biochem Biophys Res Commun       Date:  1986-07-31       Impact factor: 3.575

5.  The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor.

Authors:  J Massagué; M P Czech
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

6.  Purification of human platelet-derived growth factor.

Authors:  H N Antoniades; C D Scher; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

7.  Control of entry of Swiss 3T3 cells into S phase by fibroblast growth factor under serum-free conditions.

Authors:  G D Shipley; R G Ham
Journal:  Exp Cell Res       Date:  1983-07       Impact factor: 3.905

8.  Epidermal growth factor in blood.

Authors:  A P Savage; V K Chatterjee; H Gregory; S R Bloom
Journal:  Regul Pept       Date:  1986-12-30

9.  Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein.

Authors:  D J Knauer; G L Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  3 in total

Review 1.  Strategies for optimising serum-free media.

Authors:  G Hewlett
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  Chemical heterogeneity as a result of hydroxylamine cleavage of a fusion protein of human insulin-like growth factor I.

Authors:  E Canova-Davis; M Eng; V Mukku; D H Reifsnyder; C V Olson; V T Ling
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

3.  Human recombinant insulin-like growth factor I. II. Binding characterization and radioreceptor assay development using Balb/c 3T3 mouse embryo fibroblasts.

Authors:  K P Karey; T L Riss; B D Burleigh; D Parker; D A Sirbasku
Journal:  In Vitro Cell Dev Biol       Date:  1988-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.